On May 22, 2023, Boehringer Ingelheim announced that the FDA has approved the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). According to a previous announcement from Boehringer ...

Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...

At the beginning of July, seven additional Humira ® (adalimumab) biosimilars, including one interchangeable, joined Amjevita™ (adalimumab-atto) in the US marketplace. Abrilada™ (adalimumab-afzb) is ...

Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s ...

Cyltezo (adalimumab-adbm) is a prescription injection that’s used to treat certain autoimmune conditions. The drug comes as a liquid solution in a prefilled syringe or injection pen. It’s usually ...

Cyltezo (adalimumab-adbm) is a brand-name drug prescribed for certain inflammatory conditions. It’s available as an injection pen and a single-dose prefilled syringe. The cost of Cyltezo with and ...

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...

The collaboration will make lower‑cost biosimilar alternatives to Humira and Stelara available to commercial members.